Back to Search Start Over

Nanoparticles (NPs)-mediated Siglec15 silencing and macrophage repolarization for enhanced cancer immunotherapy.

Authors :
Liu X
Zhang Q
Liang Y
Xiong S
Cai Y
Cao J
Xu Y
Xu X
Wu Y
Lu Q
Xu X
Luo B
Source :
Acta pharmaceutica Sinica. B [Acta Pharm Sin B] 2023 Dec; Vol. 13 (12), pp. 5048-5059. Date of Electronic Publication: 2023 Jul 17.
Publication Year :
2023

Abstract

T cell infiltration and proliferation in tumor tissues are the main factors that significantly affect the therapeutic outcomes of cancer immunotherapy. Emerging evidence has shown that interferon-gamma (IFN γ ) could enhance CXCL9 secretion from macrophages to recruit T cells, but Siglec15 expressed on TAMs can attenuate T cell proliferation. Therefore, targeted regulation of macrophage function could be a promising strategy to enhance cancer immunotherapy via concurrently promoting the infiltration and proliferation of T cells in tumor tissues. We herein developed reduction-responsive nanoparticles (NPs) made with poly (disulfide amide) (PDSA) and lipid-poly (ethylene glycol) (lipid-PEG) for systemic delivery of Siglec15 siRNA (siSiglec15) and IFN γ for enhanced cancer immunotherapy. After intravenous administration, these cargo-loaded could highly accumulate in the tumor tissues and be efficiently internalized by tumor-associated macrophages (TAMs). With the highly concentrated glutathione (GSH) in the cytoplasm to destroy the nanostructure, the loaded IFN γ and siSiglec15 could be rapidly released, which could respectively repolarize macrophage phenotype to enhance CXCL9 secretion for T cell infiltration and silence Siglec15 expression to promote T cell proliferation, leading to significant inhibition of hepatocellular carcinoma (HCC) growth when combining with the immune checkpoint inhibitor. The strategy developed herein could be used as an effective tool to enhance cancer immunotherapy.<br />Competing Interests: The authors declare no conflicts of interest.<br /> (© 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.)

Details

Language :
English
ISSN :
2211-3835
Volume :
13
Issue :
12
Database :
MEDLINE
Journal :
Acta pharmaceutica Sinica. B
Publication Type :
Academic Journal
Accession number :
38045048
Full Text :
https://doi.org/10.1016/j.apsb.2023.07.012